Detection and treatment of CD30
The application provides methods of diagnosis, prognosis, prophylaxis and treatment of CD30 + cancers.
1. A method of treating a CD30 positive cancer, comprising
administering an effective regimen of a CD30-directed therapy to a patient having a cancer selected from ovarian serous carcinoma, triple negative breast cancer, anaplastic thyroid carcinoma, pancreatic carcinoma or adenocarcinoma, small cell lung cancer, anal squamous cell carcinoma, Leydig cell tumor and Sertoli cell tumor, having detectable expression of CD30, wherein the CD30-directed therapy is an antibody drug conjugate, which is brentuximab vedotin.
2. The method of claim 1 , wherein CD30 expression is detected in at least 10% of malignant or atypical cells in a sample of the cancer.
3. The method of claim 2 wherein at least 50% of the malignant or atypical cells in the sample express CD30.
4. The method of claim 2 , wherein CD30 expression is detected in the cell membrane and/or Golgi of at least 10% of the malignant or atypical cells in the sample.
5. The method of claim 1 , wherein the patient has ovarian serous carcinoma.
6. The method of claim 1 , wherein the patient has triple negative breast cancer.
7. The method of claim 1 , wherein the patient has anaplastic thyroid carcinoma.
8. The method of claim 1 , wherein the patient has pancreatic carcinoma or adenocarcinoma.
9. The method of claim 1 , wherein the patient has small cell lung cancer.
10. The method of claim 1 , wherein the patient has anal squamous cell carcinoma.
11. The method of claim 1 , wherein the patient has Leydig cell tumor.
12. The method of claim 1 , wherein the patient has Sertoli cell tumor.
13. The method of claim 1 , wherein brentuximab vedotin is administered at a dose of 1.8 mg/kg every three weeks.